ArticleFrontiers in neurology

Real-world outcomes after switching from standard therapy to efgartigimod in five patients with chronic inflammatory demyelinating polyradiculoneuropathy: a case series study in Japan.

Tatsuya Imai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.